Bartlett & Co Wealth Management’s Checkpoint Therapeutics CKPT Stock Holding History

Bartlett & Co Wealth Management’s Portfolio CKPT Stock Details CKPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-19,000	Closed	-$60.8K	–	1238
2024 Q4	$60.8K	Buy	19,000 +15,000	+375%	+$50.9K	﹤0.01%	606
2024 Q3	$8.96K	Hold	4,000	–	–	﹤0.01%	923
2024 Q2	$8.6K	Hold	4,000	–	–	﹤0.01%	933
2024 Q1	$8.2K	Hold	4,000	–	–	﹤0.01%	932
2023 Q4	$9.04K	Sell	4,000 -1,000	-20%	-$2.18K	﹤0.01%	1016
2023 Q3	$8.5K	Hold	5,000	–	–	﹤0.01%	947
2023 Q2	$12.3K	Hold	5,000	–	–	﹤0.01%	900
2023 Q1	$11.3K	Hold	5,000	–	–	﹤0.01%	805
2022 Q4	$25.6K	Hold	5,000	–	–	﹤0.01%	675
2022 Q3	$52K	Hold	5,000	–	–	﹤0.01%	558
2022 Q2	$51.5K	Hold	5,000	–	–	﹤0.01%	564
2022 Q1	$88.5K	Hold	5,000	–	–	﹤0.01%	503
2021 Q4	$156K	Buy	+5,000	New	+$166K	﹤0.01%	399

Other funds holding CKPT

BCM

Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

OBAM

ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

GCIA

Gabelli & Co Investment Advisers Rye, New York $674M AUM 64.52% 1-Year Est. Return

GLF

Groupe la Francaise Paris, France $7.29B AUM 37.28% 1-Year Est. Return

Bartlett & Co Wealth Management's CKPT Position: Q1 2025 in Review

Bartlett & Co Wealth Management sold out of Checkpoint Therapeutics (CKPT) in Q1 2025, closing a stake of 19,000 shares — an estimated $60.8K sold.

Bartlett & Co Wealth Management first reported a position in CKPT in Q4 2021 and held it in 13 quarters. The position peaked at $156K in Q4 2021. 84 funds tracked by Wall St. Rank hold CKPT as of Q1 2025.

Bartlett & Co Wealth Management reported no remaining Checkpoint Therapeutics position as of Q1 2025 after selling out during the quarter.
Bartlett & Co Wealth Management sold 19,000 Checkpoint Therapeutics shares in Q1 2025, an estimated $60.8K.
Bartlett & Co Wealth Management first reported a position in Checkpoint Therapeutics in Q4 2021 and held it in 13 quarters.
Bartlett & Co Wealth Management's Checkpoint Therapeutics position peaked at $156K in Q4 2021.
84 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q1 2025.

Based on Bartlett & Co Wealth Management's 13F filing for Q1 2025, filed 24 Apr 2025.